Cordycepin as a sensitizer to tumour necrosis factor (TNF)-α-induced apoptosis through eukaryotic translation initiation factor 2α (eIF2α)- and mammalian target of rapamycin complex 1 (mTORC1)-mediated inhibition of nuclear factor (NF)-κB

Clinical and Experimental Immunology

Volumn 168, Issue 3, 2012, Pages 325-332

  Kadomatsu, M ^a   Nakajima, S ^a   Kato, H ^a   Gu, L ^a   Chi, Y ^a   Yao, J ^a   Kitamura, M ^a  

^a UNIVERSITY OF YAMANASHI   (Japan)

Author keywords

Cordycepin; EIF2 ; MTORC1; NF B; TNF

Indexed keywords

ADENOSINE A3 RECEPTOR; CORDYCEPIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INITIATION FACTOR 2ALPHA; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; RAPAMYCIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; APOPTOSIS; ARTICLE; CONTROLLED STUDY; CORDYCEPS; DRUG ACTIVITY; DRUG MECHANISM; NONHUMAN; PRIORITY JOURNAL; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; RAT;

ANIMALS; APOPTOSIS; CELL LINE; CELL SURVIVAL; CORDYCEPS; DEOXYADENOSINES; EIF-2 KINASE; EPITHELIAL CELLS; KIDNEY TUBULES; NF-KAPPA B; NUCLEOSIDE TRANSPORT PROTEINS; PHOSPHORYLATION; RATS; RECEPTOR, ADENOSINE A3; SIGNAL TRANSDUCTION; SIROLIMUS; TOR SERINE-THREONINE KINASES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84859949262     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2012.04580.x     Document Type: Article

References (34)

1. Baud V, Karin M. Signal transduction by tumor necrosis factor and its relatives. Trends Cell Biol 2001; 11:372-7.
2. Wang CY, Mayo MW, Korneluk RG, Goeddel DV, Baldwin AS Jr. NF-κB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 1998; 281:1680-3.
3. Wajant H, Henkler F, Scheurich P. The TNF-receptor-associated factor family: scaffold molecules for cytokine receptors, kinases and their regulators. Cell Signal 2001; 13:389-400.
4. Cho HJ, Cho JY, Rhee MH, Kim HS, Lee HS, Park HJ. Inhibitory effects of cordycepin (3′-deoxyadenosine), a component of Cordyceps militaris, on human platelet aggregation induced by thapsigargin. J Microbiol Biotechnol 2007; 17:1134-8.
5. Nakamura K, Konoha K, Yoshikawa N etal. Effect of cordycepin (3'-deoxyadenosine) on hematogenic lung metastatic model mice. In Vivo 2005; 19:137-41.
6. Koc Y, Urbano AG, Sweeney EB, McCaffrey R. Induction of apoptosis by cordycepin in ADA-inhibited TdT-positive leukemia cells. Leukemia 1996; 10:1019-24.
7. De Julian-Ortiz JV, Galvez J, Munoz-Collado C, Garcia-Domenech R, Gimeno-Cardona C. Virtual combinatorial syntheses and computational screening of new potential anti-herpes compounds. J Med Chem 1999; 42:3308-14.
8. Sugar AM, McCaffrey RP. Antifungal activity of 3'-deoxyadenosine (cordycepin). Antimicrob Agents Chemother 1998; 42:1424-7.
9. Kim HG, Shrestha B, Lim SY etal. Cordycepin inhibits lipopolysaccharide-induced inflammation by the suppression of NF-κB through Akt and p38 inhibition in RAW264.7 macrophage cells. Eur J Pharmacol 2006; 545:192-9.
10. Wu WC, Hsiao JR, Lian YY, Lin CY, Huang BM. The apoptotic effect of cordycepin on human OEC-M1 oral cancer cell line. Cancer Chemother Pharmacol 2007; 60:103-11.
11. Chen LS, Stellrecht CM, Gandhi V. RNA-directed agent, cordycepin, induces cell death in multiple myeloma cells. Br J Haematol 2008; 140:682-91.
12. Shi P, Huang Z, Tan X, Chen G. Proteomic detection of changes in protein expression induced by cordycepin in human hepatocellular carcinoma BEL-7402 cells. Methods Find Exp Clin Pharmacol 2008; 30:347-53.
13. Kitamura M, Kato H, Saito Y etal. Aberrant, differential and bidirectional regulation of the unfolded protein response towards cell survival by 3′-deoxyadenosine. Cell Death Differ 2011; 18:1876-88.
14. Ariga A, Namekawa J, Matsumoto N, Inoue J, Umezawa K. Inhibition of tumor necrosis factor-α-induced nuclear translocation and activation of NF-κB by dehydroxymethylepoxyquinomicin. J Biol Chem 2002; 277:24625-30.
15. Gross S, Piwnica-Worms D. Monitoring proteasome activity in cellulo and in living animals by bioluminescent imaging: technical considerations for design and use of genetically encoded reporters. Methods Enzymol 2005; 399:512-30.
16. Kitamura M, Suto T, Yokoo T, Shimizu F, Fine LG. Transforming growth factor-β1 is the predominant paracrine inhibitor of macrophage cytokine synthesis produced by glomerular mesangial cells. J Immunol 1996; 156:2964-71.
17. Rollins BJ, Morrison ED, Stiles CD. Cloning and expression of JE, a gene inducible by platelet-derived growth factor and whose product has cytokine-like properties. Proc Natl Acad Sci USA 1988; 85:3738-42.
18. Nakamura K, Yoshikawa N, Yamaguchi Y, Kagota S, Shinozuka K, Kunitomo M. Antitumor effect of cordycepin (3′-deoxyadenosine) on mouse melanoma and lung carcinoma cells involves adenosine A3 receptor stimulation. Anticancer Res 2006; 26:43-7.
19. Jiang HY, Wek SA, McGrath BC etal. Phosphorylation of the α subunit of eukaryotic initiation factor 2 is required for activation of NF-κB in response to diverse cellular stresses. Mol Cell Biol 2003; 23:5651-63.
20. Deng J, Lu PD, Zhang Y etal. Translational repression mediates activation of NF-κB by phosphorylated translation initiation factor 2. Mol Cell Biol 2004; 24:10161-8.
21. Boyce M, Bryant KF, Jousse C etal. A selective inhibitor of eIF2α dephosphorylation protects cells from ER stress. Science 2005; 307:935-9.
22. Nakajima S, Hiramatsu N, Hayakawa K etal. Selective abrogation of BiP/GRP78 blunts activation of NF-κB through the ATF6 branch of the UPR: involvement of C/EBPβ and mTOR-dependent dephosphorylation of Akt. Mol Cell Biol 2011; 31:1710-18.
23. Novoa I, Zeng H, Harding HP, Ron D. Feedback inhibition of the unfolded protein response by GADD34-mediated dephosphorylation of eIF2α. J Cell Biol 2001; 153:1011-22.
24. Inoki K, Li Y, Zhu T, Wu J, Guan KL. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol 2002; 4:648-57.
25. Shaw RJ. LKB1 and AMP-activated protein kinase control of mTOR signalling and growth. Acta Physiol (Oxf) 2009; 196:65-80.
26. Chi Y, Li K, Yan Q etal. Nonsteroidal anti-inflammatory drug flufenamic acid is a potent activator of AMPK. J Pharmacol Exp Ther 2011; 339:257-66.
27. Ozes ON, Mayo LD, Gustin JA, Pfeffer SR, Pfeffer LM, Donner DB. NF-κB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature 1999; 401:82-5.
28. Tremblay F, Marette A. Amino acid and insulin signaling via the mTOR/p70 S6 kinase pathway. A negative feedback mechanism leading to insulin resistance in skeletal muscle cells. J Biol Chem 2001; 276:38052-60.
29. Park S, Zhao D, Hatanpaa KJ etal. RIP1 activates PI3K-Akt via a dual mechanism involving NF-κB-mediated inhibition of the mTOR-S6K-IRS1 negative feedback loop and down-regulation of PTEN. Cancer Res 2009; 69:4107-11.
30. Müller WE, Seibert G, Beyer R, Breter HJ, Maidhof A, Zahn RK. Effect of cordycepin on nucleic acid metabolism in L5178Y cells and on nucleic acid-synthesizing enzyme systems. Cancer Res 1977; 37:3824-33.
31. Misseri R, Meldrum DR, Dinarello CA etal. TNF-α mediates obstruction-induced renal tubular cell apoptosis and proapoptotic signaling. Am J Physiol Renal Physiol 2005; 288:F406-11.
32. Choi DE, Jeong JY, Lim BJ, Na KR, Shin YT, Lee KW. Pretreatment with the tumor necrosis factor-α blocker etanercept attenuated ischemia-reperfusion renal injury. Transplant Proc 2009; 41:3590-6.
33. Ben-Neriah Y, Karin M. Inflammation meets cancer, with NF-κB as the matchmaker. Nat Immunol 2011; 12:715-23.
34. Yoshikawa N, Nakamura K, Yamaguchi Y, Kagota S, Shinozuka K, Kunitomo M. Antitumour activity of cordycepin in mice. Clin Exp Pharmacol Physiol 2004; 31 (Suppl. 2):S51-3.